Helios: Research, Dosing, and Where to Buy in 2026
A research-first profile for Helios, aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
We were unable to verify the underlying compound, mechanism, or peer-reviewed evidence for Helios. It may be a branded blend, a research-stage compound with thin literature, or a name without a single canonical formulation. Do not assume safety based on this page existing. Independently verify what the product actually contains, talk to a qualified clinician, and check current regulatory status before any consumption decision. We list it educationally so that curiosity doesn't lead someone to unverified sources.
Helios is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers, and 5 transcript dosing protocols for Helios, each linked to its source.
- 5 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Helios?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Helios Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Vigorous Steve | Do This To Get Rid Of That Last Bit Of Stubborn Body Fat, Spot... | 00:07:59 | Subcutaneous injection into stubborn fat areas (lower back, glutes, hamstring tie-in, lower abs); dose very carefully due to high bioavailability | anecdotal |
| Vigorous Steve | Staying Dry On A Cut, Injectable Oral AAS, Sleep: GH Secretagogues... | 00:10:57 | Subcutaneous injection at site of stubborn fat for localized lipolysis (clenbuterol + yohimbine blend) | anecdotal |
| Vigorous Steve | Low-Dose MENT Year-Round, Melt Love Handle Fat, Injectable YK-11,... | 00:50:09 | 0.5 cc bilateral with glucagon for localized fat loss; formulation 40 mcg clen + 5 mg yohimbine per cc | anecdotal |
| Vigorous Steve | GH Secretagogues Vs Real GH, Managing Estradiol On Cycle,... | 00:08:26 | Pre-workout injectable: 20mcg clenbuterol + 1.5mg yohimbine per dose; used for spot fat reduction | anecdotal |
| Vigorous Steve | FULL Quad Tear Recovery Protocol, HGH Serum Tests, Maximize Cardio... | 00:25:17 | Helios = clenbuterol + yohimbine injectable cocktail (Belligos brand) | anecdotal |
Where to Buy Helios in 2026
No tracked vendor recommendations for Helios yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Helios. Each line links to the original source.
- "In this secondary analysis of HELIOS-B, we evaluated vutrisiran's effects on echocardiographic measures of cardiac structure and function in patients with ATTR-CM receiving vutrisiran or placebo (n = 654, 93% men)." · Jering K et al, 2025 PubMed
- "The geometric mean fold-change ratios (vutrisiran/placebo) were 0.68 (95% CI: 0.61-0.76) for NT-proBNP and 0.68 (95% CI: 0.62-0.75) for troponin I (P < 0.0001 for both)." · Maurer M et al, 2025 PubMed
- "In the overall population, vutrisiran reduced the risk of ACM (HR: 0.64; 95% CI: 0.46-0.88) and CV mortality (HR: 0.67; 95% CI: 0.47-0.96) vs placebo." · Witteles R et al, 2025 PubMed
- "Overall, 321 patients (49.1%) had ≥1 outpatient worsening HF, 245 (37.5%) had ≥1 CV event(s), and 120 (18.3%) died; 237 patients (36.2%) had no events." · Fontana M et al, 2025 PubMed
- "In recurrent event analyses over the double-blind period, vutrisiran vs placebo reduced the rate of outpatient worsening HF (relative rate ratio: 0.66; 95% CI: 0.56-0.78)." · Fontana M et al, 2025 PubMed
- "Vutrisiran also reduced the risk of the composite of all-cause mortality, CV events, and outpatient worsening HF vs placebo (HR: 0.69; 95% CI: 0.57-0.83)." · Fontana M et al, 2025 PubMed
- "In HELIOS-B, vutrisiran was tested against placebo and demonstrated a 28% reduction in the composite of all-cause mortality and recurrent cardiovascular events." · Girard A et al, 2025 PubMed
- "The transcription factor Helios, a member of the Ikaros transcription factor family, is expressed in 60-70% of Treg cells in both mouse and man, and is believed to be a marker of tTreg cells." · Thornton A et al, 2019 PubMed
Research and Studies
8 PubMed-indexed papers reference Helios. Top 8 shown.
Legal Status
Helios is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Helios FDA-approved?
Helios is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for Helios?
This page aggregates 5 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on Helios?
8 PubMed-indexed paper(s) reference Helios in our current research feed. See the Research and Studies section above for citations.